Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

993.91 +6.64 (+0.67%)
Streaming Delayed Price Updated: 10:11 AM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Novartis Terminates Three Beovu Studies in Ocular Disorders Citing Patient Safety
Novartis AG (NYSE: NVS) has announced that three Phase 3 studies evaluating Beovu (brolucizumab) in patients with retinal diseases will be terminated early after... 
Via Benzinga
Regeneron Just Got a COVID-19 Boost
It may be short lived. 
Via The Motley Fool
Exposures COVID-19
The Surprising Move Vir Stock Made After Winning Covid Drug Authorization
GlaxoSmithKline and Vir Biotechnology won Food and Drug Administration authorization for a Covid treatment on Wednesday, but Vir stock slipped Thursday. 
Via Investor's Business Daily
Exposures COVID-19
3 Stocks to Build Your Portfolio Around
These investments will help you diversify while giving you a good mix of dividends, growth, and stability. 
Via The Motley Fool
Regeneron-Sanofi's Libtayo Scores CHMP's Positive Opinion For Two Advanced Cancer Settings
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions for Regeneron Pharmaceuticals Inc (... 
Via Benzinga
Earnings Scheduled For May 6, 2021
Companies Reporting Before The Bell • ViacomCBS (NASDAQ:VIAC) is projected to report quarterly earnings at $1.22 per share on revenue of $7.30 billion. • Cohen... 
Via Benzinga
Facebook And Regeneron Lead The Nasdaq Lower Tuesday
U.S. indices were trading lower Tuesday after U.S. Treasury Secretary Janet Yellen called for business leaders across the country to pay highe... 
Via Benzinga
Sanofi-Regeneron Tout New Data For Dupixent From Pediatric Asthma Trial
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have unveiled detailed results from a Phase 3 trial evaluating Dupixent... 
Via Benzinga
The QQQ Was Hammered Again Today. Here's Why.
U.S. indices were trading lower across the board Wednesday after CPI data showed an increase in U.S. inflation, which has weighed on stocks. 
Via Benzinga
Tesla, Qualcomm Plummet, Lead QQQ Sharply Lower Monday
The Nasdaq and companies in the broader technology sector were trading lower Monday amid profit-taking and overall weakness in the sector. Here&rsq... 
Via Benzinga
Cathie Wood Buys $26M Disney Shares And Sells $13M In Netflix: What You Need To Know
Cathie Wood-led Ark Investment Management on Friday bought 150,556 shares, worth about $26.15 million, in Walt Disney Co (NYSE: DIS), marking its debut in the media and... 
Via Benzinga
Review Of Present Therapies For Covid-19
A summary of authorized drugs for Covid-19, those in development, and those that have failed. 
Via Talk Markets
Exposures COVID-19
ARKK Stocks Breakdowns and Bounces
After struggling for most of the past couple of months, momentum and Tech stocks are broadly outperforming today. 
Via Talk Markets
Cathie Wood Sheds $33.6M Alibaba Shares On Earnings Day
Cathie Wood-led Ark Investment Management on Thursday shed 162,840 shares, worth about $33.6 million, in Alibaba Group Holding (NYSE: BABA) after the company posted its first... 
Via Benzinga
Return On Capital Employed Overview: Regeneron Pharmaceuticals
Regeneron Pharmaceuticals (NASDAQ:REGN) posted a 4.65% decrease in earnings from Q4. Sales, however, increased by 4.37% over the previous quarter to $2.53 billion. Despite the... 
Via Benzinga
Cathie Wood Piles Up Palantir For Third Day In A Row, Adding $39M Worth Of Shares
Cathie Wood-led Ark Investment Management on Wednesday snapped up 2.07 million shares, worth about $39 million, in Palantir Technologies Inc (NYSE: PLTR), on a day the... 
Via Benzinga
Regeneron Pharmaceuticals Inc (REGN) Q1 2021 Earnings Call Transcript
REGN earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Ocugen Shares Sink Despite OCU200 Being Comparable To Aflibercept In Reducing Neovascularization, Damage To Retina In Animal Study
Ocugen Inc (NASDAQ: OCGN) has announced the presentation of new preclinical data evaluating the efficacy of OCU200 in in-vitro and in-vivo models for ocular... 
Via Benzinga
Cathie Wood Loads Up $57M In Palantir As Stock Stages Reversal On Q1 Earnings Beat
Cathie Wood-led Ark Investment Management on Tuesday snapped up 2.8 million shares, worth about $56.7 million, in Palantir Technologies Inc (NYSE: PLTR) after the data analytics... 
Via Benzinga
Looking Into Regeneron Pharmaceuticals's Return On Capital Employed
Looking Into Regeneron Pharmaceuticals's Return On Capital Employed Regeneron Pharmaceuticals (NASDAQ:REGN) posted a 4.65% decrease in earnings from Q4. Sales, however, increased... 
Via Benzinga
Cathie Wood Cuts Apple Stake By 30% And Buys Coinbase, DraftKings
Cathie Wood-led Ark Investment Management shed more shares of Apple Inc (NASDAQ: 
Via Benzinga
Why Regeneron's Q1 Results Looked Great Despite Its Revenue Miss
The big biotech delivered impressive revenue and earnings growth. 
Via The Motley Fool
Regeneron Reports Mixed Bag On Q1 Earnings; Eylea Franchise Boosts Revenue
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned $9.89 per share for the first quarter, beating the $9.03 estimate. Revenue of $2.53 billion narrowly missed... 
Via Benzinga
Cathie Wood Slashes Apple Stake To Half — Also Trims Google, Fastly: What You Need To Know
Cathie Wood-led Ark Investment Management nearly halved the Apple Inc (NASDAQ: AAPL) stake in the ARK Fintech Innovation ETF (NYSE: ARKF) on Thursday. ARKF shed 298,505 Apple... 
Via Benzinga
Regeneron Pharmaceuticals: Q1 Earnings Insights
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) decreased 0.1% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 49.... 
Via Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Regeneron Earnings Top, Biotech Giant Edges Higher
Regeneron earnings comfortably beat Q1 views while sales were in line. The biotech giant edged higher before Thursday's open. 
Via Investor's Business Daily
Cathie Wood Loads Up More On Peloton, Skillz, Teladoc On The Dip
Cathie Wood-led Ark Investment Management snapped up over 3 million shares, worth about $48.53 million, in Skillz Inc (NYSE: SKLZ) on Wednesday. SKLZ shares closed 9% lower... 
Via Benzinga
India Gives Emergency Use Nod To Roche-Regeneron's COVID-19 Antibody Cocktail
Roche Holdings AG (OTCMKTS: RHHBY) has received Emergency Use Authorization in India for its investigational antibody cocktail (casirivimab and imdevimab) for... 
Via Benzinga
Exposures COVID-19
Cathie Wood Loaded Up Further On Skillz On Earnings Day
Cathie Wood-led Ark Investment Management snapped up over 3 million shares, worth about $52.1 million, in Skillz Inc (NYSE: SKLZ) ahead of the mobile gaming company’s first-... 
Via Benzinga
< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.